Want to see HK:2252 full AI Analyst Report?
2252 Stock Chart & Stats
HK$34.14
-HK$0.03(-0.33%)
At close: 4:00 PM EST
HK$34.14
-HK$0.03(-0.33%)
Day’s Range― - ―
52-Week RangeHK$17.80 - HK$35.34
Previous CloseN/A
Volume4.35M
Average Volume (3M)5.91M
Market Cap
HK$25.37B
Enterprise ValueHK$21.20B
Total Cash (Recent Filing)HK$640.42M
Total Debt (Recent Filing)HK$426.37M
Price to Earnings (P/E)―
Beta2.23
Next Earnings
Sep 02, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding1,030,720,600
10 Day Avg. Volume5,228,361
30 Day Avg. Volume5,906,894
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)54.27
Price to Sales (P/S)40.46
P/FCF Ratio-574.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$39.16Price Target Upside14.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$1.13B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA ~61% revenue acceleration in 2025 signals durable commercial traction for surgical-robotics platforms. Sustained top-line expansion supports scale advantages, improves per-unit absorption of fixed R&D and SG&A, and creates a clearer path to operating leverage as adoption broadens across hospitals.
Gross MarginA positive ~29% gross margin indicates the company has fundamentally viable unit economics on its robotic systems and consumables. With scalable manufacturing and higher volumes, this margin level provides a structural runway for converting revenue growth into future operating profit once fixed costs and sales efficiency improve.
Leverage ImprovementMaterial reduction in leverage (debt-to-equity ~1.0 from ~2.5) lowers financial risk and interest burden, improving solvency. A stronger capital structure increases flexibility for product investment or clinical expansion and reduces the structural probability of distress over the medium term.
Bears Say
Sustained UnprofitabilityDeep net losses (net margin ~-45%) and severely negative ROE (~-59%) indicate the business is not yet generating shareholder returns. Persistent unprofitability erodes equity, hampers reinvestment capacity, and makes achieving self-sustaining growth contingent on substantial margin improvement or ongoing external funding.
Negative Cash FlowContinued negative operating and free cash flow means the company remains cash burn-dependent. Even with improved trends, the deterioration and volatility in free cash flow versus prior years imply ongoing reliance on financing, which constrains strategic choices and increases dilution or refinancing risk over the medium term.
Equity & Return PressureDeclining equity combined with very negative returns weakens the capital buffer available for investment or downturns. This structural pressure raises the likelihood of dilution or costly financing to fund expansion, and reduces resilience against clinical, competitive, or regulatory setbacks over the coming months.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H News
2252 FAQ
What was Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price range in the past 12 months?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H lowest stock price was HK$17.80 and its highest was HK$35.34 in the past 12 months.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap is HK$25.37B.
When is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 47 days.
How were Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s earnings last quarter?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H released its earnings results on Mar 26, 2026. The company reported -HK$0.162 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price is currently Undervalued.
Does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H pay dividends?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H does not currently pay dividends.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate is -0.01.
How many shares outstanding does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H have?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H has 1,030,720,600 shares outstanding.
What happened to Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H reported an EPS of -HK$0.162 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.136%.
Which hedge fund is a major shareholder of Shanghai MicroPort MedBot (Group) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2252
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.00%
12-Months-Change
Fundamentals
Return on Equity
-52.78%
Trailing 12-Months
Asset Growth
9.21%
Trailing 12-Months
Company Description
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. focuses on the comprehensive research, development, design, production, and distribution of surgical robotic systems, catering to markets in China and Europe. Their innovative product range features Toumai, a versatile laparoscopic surgical robot employed in urologic, gynecologic, thoracic, and general surgeries. They also provide DFVision, a 3D electronic laparoscope designed to improve visualization during abdominal, thoracic, and pelvic operations. For orthopedic procedures, the Honghu robot aids in knee and hip joint replacements, while the R-One system is specifically engineered for vascular interventions like coronary angioplasty. The iSR'obot, known as the Mona Lisa robotic system, specializes in transperineal prostate biopsies. Additionally, the company's offerings extend to specialized robots for spinal procedures, trans-bronchial diagnosis and treatment, TAVR (Transcatheter Aortic Valve Replacement), and automated needle-targeting systems for precise percutaneous lung biopsies and nephrolithotomy. Founded in 2014 and headquartered in Shanghai, China, the company functions as a subsidiary of MicroPort Scientific Corporation.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Earnings & Revenues
2252 Stock 12 Month Forecast
Average Price Target
HK$39.16
▲(14.69% Upside)
Technical Analysis
MicroPort Scientific
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―